Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy
Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy
复制标题
DOI：
10.1182/blood-2010-06-291922
复制
发表时间：
2010-12-16
期刊：
影响因子：
20.3
通讯作者：
Marin, David
中科院分区：
文献类型：
--
作者：
Ibrahim, Amr R.;Paliompeis, Christos;Marin, David
我们分析了26例伊马替尼和第二种酪氨酸激酶抑制剂治疗失败但仍处于第一慢性期的慢性粒细胞白血病患者的队列，并确定了反应和结局的预后因素。既往伊马替尼或二线治疗获得细胞遗传学缓解是三线治疗获得完全细胞遗传学缓解的唯一独立预测因素。年龄较小和二线治疗细胞遗传学缓解是总生存期（OS）的唯一独立预测因素。在3个月时，9例达到细胞遗传学缓解的患者的30个月完全细胞遗传学缓解概率和OS优于未达到缓解的患者。三线治疗开始前可测量的因素和3个月时的细胞遗传学缓解可准确预测后续结局，从而指导临床决策。（血。2010; 116（25）：5497-5500）
We analyzed a cohort of 26 patients with chronic myeloid leukemia who had failed imatinib and a second tyrosine kinase inhibitor but were still in first chronic phase and identified prognostic factors for response and outcomes. The achievement of a prior cytogenetic response on imatinib or on second-line therapy were the only independent predictors for the achievement of complete cytogenetic responses on third-line therapy. Younger age and the achievement of a cytogenetic response on second line were the only independent predictors for overall survival (OS). At 3 months, the 9 patients who had achieved a cytogenetic response had better 30-month probabilities of complete cytogenetic responses and OS than the patients who had failed to do so. Factors measurable before starting treatment with third line therapy and cytogenetic responses at 3 months can accurately predict subsequent outcome and thus guide clinical decisions. (Blood. 2010; 116(25): 5497-5500)